Ishita Drugs & Industries Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2025, revealing a mixed performance amidst ongoing facility upgrades.

Financial Performance

The company reported revenue from operations of Rs. 806.81 lakhs for the quarter, contributing to a half-yearly revenue of Rs. 1499.73 lakhs. However, the net profit for the quarter saw a decline, coming in at Rs. 14.33 lakhs compared to Rs. 30.23 lakhs in the previous quarter.

The basic earnings per share (EPS) from continuing operations stood at Rs. 0.48 for the quarter.

Manufacturing Facility Upgrade

Ishita Drugs & Industries is currently undertaking a significant manufacturing facility upgradation project to comply with the Revised Schedule M regulations. The company's Board of Directors discussed the progress of this project during their meeting. Key points include:

1. Appointment of a civil contractor and commencement of construction.
2. Progress affected by higher-than-normal rainfall and an extended monsoon period.
3. Expenditure of nearly Rs. 50 lakhs incurred towards civil construction of the project.

Balance Sheet Highlights

As of September 30, 2025, the company's financial position shows:

Cash Flow and Liquidity

The cash flow statement reveals:

• Net cash generated from operating activities: Rs. 412.24 lakhs
• Net cash used in investing activities: Rs. 245.67 lakhs
• Net cash used in financing activities: Rs. 177.27 lakhs

This resulted in a net decrease of Rs. 10.70 lakhs in cash and cash equivalents for the half-year period.

The company maintains a strong liquidity position with cash and cash equivalents of Rs. 46.14 lakhs and bank balances of Rs. 426.54 lakhs as of September 30, 2025.

Ishita Drugs & Industries Limited continues to navigate through challenging market conditions while investing in its future growth through facility upgrades. The impact of these investments on the company's financial performance and market position remains to be seen in the coming quarters.

Ishita Drugs & Industries , a pharmaceutical company, has witnessed continued investment from Ishita Pharmaceuticals, a related party, which has further increased its shareholding in the company. Following an earlier acquisition, Ishita Pharmaceuticals has made an additional purchase, demonstrating sustained interest in the target company.

Latest Transaction Details

In the most recent transaction dated December 08, 2025, Ishita Pharmaceuticals acquired an additional 560 shares of Ishita Drugs & Industries through open market purchase. Each share carries a face value of Rs. 10.00, representing a 0.02% increase in shareholding.

Updated Shareholding Pattern

The cumulative effect of Ishita Pharmaceuticals' investments has resulted in a progressive increase in its stake in Ishita Drugs & Industries.

Company Capital Structure

The equity share capital of Ishita Drugs & Industries remains unchanged at Rs. 29,903,000.00, comprising 2,990,300 shares with a face value of Rs. 10.00 each. The recent acquisition does not impact the overall capital structure of the company.

Regulatory Compliance and Documentation

In accordance with SEBI regulations, specifically Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, both companies have filed the necessary disclosures. Ishita Drugs & Industries communicated the transaction details to BSE Limited on December 10, 2025, while Ishita Pharmaceuticals submitted its disclosure on December 09, 2025.

Market Implications

The progressive increase in shareholding by Ishita Pharmaceuticals, from an initial entry to now holding 1.02% of voting rights, indicates a strategic interest in Ishita Drugs & Industries. As related parties, this continued investment pattern suggests potential for enhanced collaboration and strategic alignment between the two pharmaceutical entities. The company is listed on BSE Limited under scrip code 524400.